Sheet 1 of 3

Form PTO-1449

INFORMATION DISCLOSURE STATEMENT
IN AN APPLICATION

(Use several sheets if necessary)

Docket No. (optional)
010094.04Application Number:
10/826,447Applicant:
Tian *et al.*Filing Date:
Apr. 16, 2004Group Art Unit:
(as yet unknown)

U.S. PATENT DOCUMENTS

Examiner Initial	Cite No. ¹	Document Number	Date	Name	Class	Sub-class	Filing Date if Appropriate
B.K.	A1	US 3,987,035	1976	Rinehart, Jr., <i>et al.</i>	260	239.3P	
	A2	US 4,261,989	1981	Sasaki <i>et al.</i>	424	244	
	A3	US 4,421,687	1983	Hasegawa <i>et al.</i>	260	239.3B	
	A4	US 4,421,688	1983	Muroi <i>et al.</i>	260	239.3B	
	A5	US 4,540,517	1985	Tanida <i>et al.</i>	260	239.3B	
	A6	US 5,387,584	1995	Schnur	514	183	
	A7	US 5,510,118	1996	Bosch <i>et al.</i>	424	489	
	A8	US 5,534,270	1996	De Castro	424	490	

FOREIGN PATENT DOCUMENTS

Examiner Initial	Cite No. ¹	Document Number	Date	Country	Class	Sub-class	Translation Enclosed?
B.K.	B1	WO 93/14215 A1	1993	PCT			n/a
	B2	WO 94/08578 A2	1994	PCT			n/a
	B3	WO 95/01342 A1	1995	PCT			n/a
	B4	WO 00/03737 A2	2000	PCT			n/a
	B5	WO 02/079167 A1	2002	PCT			n/a

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)

Examiner Initial	Cite No. ¹	Details of Document	Translation enclosed?
B.K.	C1	Sasaki <i>et al.</i> , <i>J. Antibiotics</i> 32 (8), 849-851 (1979), "Growth Inhibition of Virus Transformed Cells in Vitro and Antitumor Activity in Vivo of Geldanamycin and its Derivatives"	n/a
	C2	Muroi <i>et al.</i> , <i>Tetrahedron</i> 37, 1123-1130 (1981), "The Structures of Macbecins I and II"	n/a
	C3	Omura <i>et al.</i> , <i>J. Antibiotics</i> 37 (10), 1264-1267 (1984), "Chemical Modification and Antitumor Activity of Herbimycin A, 8,9-Epoxy, 7,9-Cyclic Carbamate, and 17- or 19-Amino Derivatives"	n/a

Examiner

Date considered

8/24/04

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP §609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.

¹ Applicant's unique citation designation number (optional).

Form PTO-1449 INFORMATION DISCLOSURE STATEMENT IN AN APPLICATION (Use several sheets if necessary)	Docket No. (optional) 010094.04	Application Number: 10/826,447
	Applicant: Tian <i>et al.</i>	
	Filing Date: Apr. 16, 2004	Group Art Unit: (as yet unknown)

U.S. PATENT DOCUMENTS							
Examiner Initial	Cite No. ¹	Document Number	Date	Name	Class	Sub-class	Filing Date if Appropriate
B.K.	A9	US 5,662,883	1997	Bagchi <i>et al.</i>	424	9.4	
	A10	US 5,932,566	1999	Schnur <i>et al.</i>	514	183	
	A11	US 6,015,659	2000	Welch <i>et al.</i>	435	1.2	
	A12	US 6,682,758	2004	Tabibi <i>et al.</i>	424	450	12/22/1999
	A13	US 2003/0114450 A1	2003	Santi <i>et al.</i>	514	234.5	8/5/2002


FOREIGN PATENT DOCUMENTS							
Examiner Initial	Cite No. ¹	Document Number	Date	Country	Class	Sub-class	Translation Enclosed?
B.K.	B6	WO 02/36574 A1	2002	PCT			n/a
	B7	WO 03/013430 A2	2003	PCT			n/a
	B8	WO 03/066005 A2	2003	PCT			n/a
	B9	JP 63-218620	1988	Japan			no
	B10	JP 04-046120	1990	Japan			no

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)			
Examiner Initial	Cite No. ¹	Details of Document	Translation enclosed?
B.K.	C4	Shibata <i>et al.</i> , <i>J. Antibiotics</i> 39 (11), 1630-1633 (1986), "The Structure and Cytocidal Activity of Herbimycin C"	n/a
	C5	Uehara <i>et al.</i> , <i>J. Antibiotics</i> 41 (5), 831-834 (1988), "Effects of Herbimycin Derivatives on src Oncogene Function in Relation to Antitumor Activity"	n/a
	C6	Schnur <i>et al.</i> , <i>J. Med. Chem.</i> , 38, 3806-3812 (1995), "Inhibition of Oncogene Products p185 (erbB-2) in Vitro and in Vivo by Geldanamycin and Dihydrogeldanamycin Derivatives"	n/a
	C7	Schnur <i>et al.</i> , <i>J. Med. Chem.</i> , 38, 3813-3820 (1995), "erbB-2 Oncogene Inhibition by Geldanamycin Derivatives: Synthesis, Mechanism of Action, and Structure-Activity Relationships"	n/a
	C8	Jez <i>et al.</i> , <i>Chemistry & Biology</i> , 10, 361-368 (2003), "Crystal Structure and Molecular Modeling of 17-DMAG in Complex with Human Hsp90"	n/a

Examiner <i>Brant Kiff</i>	Date considered <i>8/24/04</i>
-------------------------------	-----------------------------------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP §609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.

¹ Applicant's unique citation designation number (optional).

Sheet 3 of 3

Form PTO-1049

INFORMATION DISCLOSURE STATEMENT
IN AN APPLICATION

(Use several sheets if necessary)

Docket No. (optional)

010094.04

Application Number:

10/826,447

Applicant:

Tian *et al.*

Filing Date:

Apr. 16, 2004

Group Art Unit:

(as yet unknown)

U.S. PATENT DOCUMENTS

Examiner Initial	Cite No. ¹	Document Number	Date	Name	Class	Sub-class	Filing Date If Appropriate

FOREIGN PATENT DOCUMENTS

Examiner Initial	Cite No. ¹	Document Number	Date	Country	Class	Sub-class	Translation Enclosed?

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)

Examiner Initial	Cite No. ¹	Details of Document	Translation enclosed?
B.K.	C9	Carreras <i>et al.</i> , <i>Anal. Biochem.</i> , 317 (1), 40-46 (June 2003), "Filter Binding Assay for the Geldanamycin-Heat Shock Protein 90 Interaction"	n/a
↓	C10	Chemical Abstracts 110:231340 (abstract of JP 63-218620)	n/a
↓	C11	Chemical Abstracts 117:63002 (abstract of JP 04-046120)	n/a

Examiner

Date considered

8/24/04

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP §609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.

¹ Applicant's unique citation designation number (optional).